Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

The New England Journal of Medicine
Jennifer G RobinsonODYSSEY LONG TERM Investigators

Abstract

Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, h...Continue Reading

References

Nov 2, 2012·The New England Journal of Medicine·Eli M RothEvan A Stein
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators

❮ Previous
Next ❯

Citations

Feb 20, 2016·Journal of Clinical Lipidology·W Virgil BrownJames M McKenney
Feb 18, 2016·Naunyn-Schmiedeberg's Archives of Pharmacology·Aimo Kannt, Thomas Wieland
Apr 5, 2016·Indian Journal of Endocrinology and Metabolism·Ambika Gopalakrishnan UnnikrishnanAmbrish Mithal
Jan 30, 2016·Expert Opinion on Biological Therapy·Marcos G ValerioWilbert S Aronow
Dec 31, 2015·International Journal of Food Sciences and Nutrition·Carrie Helen Ruxton
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Eliano P NavareseMarco Matteo Ciccone
Nov 14, 2015·Expert Review of Cardiovascular Therapy·Michel Farnier
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Maria-Corina SerbanDimitri P Mikhailidis
Aug 22, 2015·Expert Opinion on Drug Metabolism & Toxicology·Michael M Page, Gerald F Watts
Sep 4, 2015·Expert Opinion on Drug Metabolism & Toxicology·Željko Reiner
Sep 4, 2015·Expert Opinion on Biological Therapy·Annukka M KiveläSeppo Ylä-Herttuala
Nov 14, 2015·Current Medical Research and Opinion·Laurence S Sperling, John R Nelson
Feb 11, 2016·Cardiovascular Drugs and Therapy·Evan A Stein, Frederick Raal
Feb 21, 2016·Cardiovascular Drugs and Therapy·Florian Kronenberg
Dec 15, 2015·European Heart Journal·Baris GencerFrançois Mach
Nov 6, 2015·European Heart Journal·Maarten L Simoons, Jaap W Deckers
Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Feb 6, 2016·Cardiovascular Drugs and Therapy·Yanhong GuoY Eugene Chen
Feb 9, 2016·Cell Metabolism·Daniel J Rader
Apr 9, 2016·Journal of Clinical Lipidology·Kathryn MatneyNicole L Draper
Jan 2, 2016·Atherosclerosis·Christina Reith, Jane Armitage
Jan 6, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American College of Endocrinology (ACE)
Oct 24, 2015·Journal of Cellular and Molecular Medicine·Tao GuoShang-Ling Pan
Dec 15, 2015·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Juan Pedro-Botet, Xavier Pintó
Oct 23, 2015·Clinical Pharmacology and Therapeutics·G P S Shantha, J G Robinson
Jan 15, 2016·Nature Reviews. Cardiology·Scott M Grundy
Aug 12, 2015·British Journal of Clinical Pharmacology·Eveline P van PoelgeestJacobus Burggraaf
Nov 10, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·A J Marian
Sep 16, 2015·Clinical Pharmacology and Therapeutics·E Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.